601 related articles for article (PubMed ID: 26507078)
1. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
3. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
[TBL] [Abstract][Full Text] [Related]
4. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D
J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
6. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
[TBL] [Abstract][Full Text] [Related]
9. Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2014 Apr; 16(4):338-46. PubMed ID: 24071797
[TBL] [Abstract][Full Text] [Related]
10. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation.
Thurgar E; Barton S; Karner C; Edwards SJ
Health Technol Assess; 2016 Mar; 20(24):v-vi, 1-486. PubMed ID: 27034016
[TBL] [Abstract][Full Text] [Related]
13. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
14. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
17. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Perlis N; Al-Kasab T; Ahmad A; Goldberg E; Fadak K; Sayyid R; Finelli A; Kulkarni G; Hamilton R; Zlotta A; Ghai S; Fleshner N
J Urol; 2018 May; 199(5):1182-1187. PubMed ID: 29175542
[TBL] [Abstract][Full Text] [Related]
18. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
19. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
